Sniffing Trouble at Aviron
Shares of Aviron (AVIR ) plunged following the resumption of trading July 30. Trading was halted on July 27. A U.S. FDA committee says data for the company's FluMist is not sufficient to support the safety of the vaccine at this time. S&P cut its opinion on Aviron to hold. CE Unterberg put its model under review. Morgan Stanley cut its price target.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.